Trevi Therapeutics Newsroom

A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $6 to $9

Futu NewsDec 13 21:00

Trevi Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesDec 13 02:02

Trevi Therapeutics Price Target Raised to $7.50/Share From $6.00 by HC Wainwright & Co.

Dow JonesDec 13 02:02

D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target

BenzingaDec 13 01:34

Trevi Therapeutics Analyst Ratings

BenzingaDec 13 01:22

Optimistic Buy Rating for Trevi Therapeutics Amid Promising Phase 2b Trial Results

TipRanksDec 12 21:59

Oppenheimer Remains a Buy on Trevi Therapeutics (TRVI)

TipRanksDec 6 00:51

B.Riley Financial Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $6

Futu NewsDec 5 23:33

Trevi Therapeutics Is Maintained at Buy by D. Boral Capital

Dow JonesDec 4 20:38

Trevi Therapeutics Price Target Maintained With a $21.00/Share by D. Boral Capital

Dow JonesDec 4 20:38

Trevi Therapeutics Analyst Ratings

BenzingaDec 4 19:23

JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8

Futu NewsNov 19 16:36

B.Riley Financial Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $6

Futu NewsNov 9 02:31

Trevi Therapeutics: Buy Rating Affirmed Amid Promising Haduvio Prospects and Upcoming Data Milestones

TipRanksNov 8 05:37

Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8

Futu NewsNov 8 05:31

Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $8

Futu NewsNov 7 23:31

Trevi Therapeutics Price Target Maintained With a $21.00/Share by EF Hutton

Dow JonesNov 7 22:00

Trevi Therapeutics Is Maintained at Buy by EF Hutton

Dow JonesNov 7 22:00

Trevi Therapeutics Analyst Ratings

BenzingaNov 7 21:50

JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8

Futu NewsNov 7 21:39